Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 66 of 95, showing 5 Applications out of 471 total, starting on record 326, ending on 330

# Protocol No Study Title Investigator(s) & Site(s)

326.

ECCT/21/12/04   FAST Study
    Assessments of the EFficacy, the onset-of-Action and the Safety of Tot'héma® in adults with moderate iron deficiency anaemia   
Principal Investigator(s)
1. Dr. Francis Xavier Otieno Odawa
Site(s) in Kenya
1. MOI University Teaching and Referral Hospital (Nandi county)
2. UNIM Research and Training Centre (Kisumu county)
3. Kenyatta National Hospital (Nairobi City county)
 
View

327.

ECCT/21/12/05   131 Inclacumab Ph 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N Nduba
4. Prof. Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
View

328.

ECCT/21/12/07   GBT 132- Inclacumab Phase 3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Videlis N Nduba
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View

329.

ECCT/22/01/01   ASTEFANIA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

330.

ECCT/22/01/02   CoVPN 3008
    Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern   
Principal Investigator(s)
1. Ben Madeke Andagalu
Site(s) in Kenya
1. KEMRI -USAMRD-A, Kombewa Clinical Research Centre (Kisumu county)
2. KEMRI-CGHR (Kisumu county)
 
View